Market closedNon-fractional
4D Molecular Therapeutics/FDMT
13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1YMAX
About 4D Molecular Therapeutics
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.
Ticker
FDMT
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
EmeryVille, United States
Employees
171
FDMT Metrics
BasicAdvanced
$1.1B
Market cap
-
P/E ratio
-$2.42
EPS
2.93
Beta
-
Dividend rate
Price and volume
Market cap
$1.1B
Beta
2.93
Financial strength
Current ratio
32.652
Quick ratio
32.062
Long term debt to equity
1.831
Total debt to equity
2.36
Management effectiveness
Return on assets (TTM)
-17.29%
Return on equity (TTM)
-25.53%
Valuation
Price to revenue (TTM)
43.54
Price to book
1.74
Price to tangible book (TTM)
1.74
Price to free cash flow (TTM)
-11.21
Growth
Revenue change (TTM)
826.31%
Earnings per share change (TTM)
-28.55%
3-year revenue growth
19.20%
3-year earnings per share growth
-21.92%
What the Analysts think about FDMT
Analyst Ratings
Majority rating from 10 analysts.
FDMT Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
-100.00%
Net income
-$32M
-67.86%
Profit margin
0.00%
-100.00%
FDMT Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.77
-$0.24
-$0.75
-$0.66
-
Expected
-$0.81
-$0.59
-$0.74
-$0.74
-$0.71
Surprise
-4.70%
-59.58%
1.18%
-10.41%
-
FDMT News
AllArticlesVideos
4DMT Presents Injection-Free Subgroup Analyses from 4D-150 Phase 2 PRISM Randomized Dose Expansion Cohort in Wet AMD Patients with Severe Disease Activity & High Treatment Burden at the Clinical Trials at the Summit 2024 Meeting
GlobeNewsWire·4 weeks ago
4DMT Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D-710 for Modulator-Ineligible/-Intolerant Cystic Fibrosis at 47th European Cystic Fibrosis Conference
GlobeNewsWire·4 weeks ago
4DMT to Present Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis at 47ᵗʰ European Cystic Fibrosis Conference
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for 4D Molecular Therapeutics stock?
4D Molecular Therapeutics (FDMT) has a market cap of $1.1B as of July 05, 2024.
What is the P/E ratio for 4D Molecular Therapeutics stock?
The price to earnings (P/E) ratio for 4D Molecular Therapeutics (FDMT) stock is 0 as of July 05, 2024.
Does 4D Molecular Therapeutics stock pay dividends?
No, 4D Molecular Therapeutics (FDMT) stock does not pay dividends to its shareholders as of July 05, 2024.
When is the next 4D Molecular Therapeutics dividend payment date?
4D Molecular Therapeutics (FDMT) stock does not pay dividends to its shareholders.
What is the beta indicator for 4D Molecular Therapeutics?
4D Molecular Therapeutics (FDMT) has a beta rating of 2.93. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell 4D Molecular Therapeutics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.